Chapter 1: Executive summary 1.1. Market scope and segmentation 1.2. Key questions answered in this study 1.3. Executive Summary Chapter 2: Global precision medicine market - market overview 2.1. Global market overview - market trends, market attractiveness analysis, geography-wise market revenue (USD) 2.2. Global market drivers and challenges 2.3. Value chain analysis – precision medicine market 2.4. Porter’s Five Forces Analysis 2.5. Market segmentation based on end use (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies) 2.5. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.5. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.5. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.5. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.6. Market segmentation for therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases) 2.6. a. Revenue from cancer therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.6. b. Revenue from cardiovascular therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.6. c. Revenue from central nervous system therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.6. d. Revenue from psychiatric disorder therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.6. e. Revenue from infectious diseases therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.7. Market segmentation based on sub-market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics) 2.7. a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.7. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.7. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.7. d. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 2.7. e. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations Chapter 3: North America precision medicine market - market overview 3.1. Market overview - market trends, market attractiveness analysis, geography wise market revenue (USD) 3.2. North America - market drivers and challenges 3.3. Market segmentation based on end use (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies) 3.3. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.3. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.3. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.3. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.4. Market segmentation based on therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases) 3.4. a. Revenue from cancer therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.4. b. Revenue from cardiovascular therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.4. c. Revenue from central nervous system therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.4. d. Revenue from psychiatric disorder therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.4. e. Revenue from infectious diseases therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.5. Market segmentation based on sub-market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics) 3.5. a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.5. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.5. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.5. d. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 3.5. e. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations Chapter 4: Europe precision medicine market- market overview 4.1. Market overview - market trends, market attractiveness analysis, geography wise market revenue (USD) 4.2. Europe - market drivers and challenges 4.3. Market segmentation based on end use (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies) 4.3. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.3. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.3. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.3. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.4. Market segmentation based on therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases) 4.4. a. Revenue in cancer therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.4. b. Revenue from cardiovascular therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.4. c. Revenue from central nervous system therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.4. d. Revenue from psychiatric disorder therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.4. e. Revenue from infectious diseases therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.5. Market segmentation based on sub-market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics) 4.5. a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.5. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.5. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.5. d. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 4.5. e. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations Chapter 5: Asia-Pacific precision medicine market - market overview 5.1. Market overview - market trends, market attractiveness analysis, geography wise market revenue (USD) 5.2. Asia-Pacific - market drivers and challenges 5.3. Market segmentation based on end use (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies) 5.3. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.3. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.3. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.3. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.4. Market segmentation based on therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases) 5.4. a. Revenue from cancer therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.4. b. Revenue from cardiovascular therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.4. c. Revenue from central nervous system therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.4. d. Revenue from psychiatric disorder therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.4. e. Revenue from infectious diseases therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.5. Market segmentation based on sub-market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics) 5.5. a. Revenue from big data analytics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.5. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.5. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.5. d. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 5.5. e. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations Chapter 6: Latin America precision medicine market - market overview 6.1. Market overview - market trends, market attractiveness analysis, geography wise market revenue (USD) 6.2. Latin America - market drivers and challenges 6.3. Market segmentation based on end use (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies) 6.3. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.3. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.3. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.3. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.4. Market segmentation based on therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases) 6.4. a. Revenue from cancer therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.4. b. Revenue from cardiovascular therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.4. c. Revenue from central nervous system therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.4. d. Revenue from psychiatric disorder therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.4. e. Revenue from infectious diseases therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.5. Market segmentation based on sub-market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics) 6.5. a. Revenue from big data analytics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.5. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.5. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.5. d. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 6.5. e. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations Chapter 7: Middle East and Africa precision medicine market - market overview 7.1. Market overview-market trends, market attractiveness analysis, geography wise market revenue (USD) 7.2. Middle East and Africa - market drivers and challenges 7.3. Market segmentation based on end use (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies) 7.3. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.3. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.3. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.3. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.4. Market segmentation based on therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases) 7.4. a. Revenue from cancer therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.4. b. Revenue from cardiovascular therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.4. c. Revenue from central nervous system therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.4. d. Revenue from psychiatric disorder therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.4. e. Revenue from infectious diseases therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.5. Market segmentation based on sub-market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics) 7.5. a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.5. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.5. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.5. d. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations 7.5. e. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations Chapter 8: Competitive landscape 8.1. Abbott Laboratories 8.1. a. Company snapshot 8.1. b. Product offerings 8.1. c. Growth strategies 8.1. d. Initiatives 8.1. e. Geographical presence 8.1. f. Key numbers 8.2. GE Healthcare 8.2. a. Company snapshot 8.2. b. Product offerings 8.2. c. Growth strategies 8.2. d. Initiatives 8.2. e. Geographical presence 8.2. f. Key numbers 8.3. GlaxoSmithKline (GSK) 8.3. a. Company snapshot 8.3. b. Product offerings 8.3. c. Growth strategies 8.3. d. Initiatives 8.3. e. Geographical presence 8.3. f. Key numbers 8.4. Johnson & Johnson 8.4. a. Company snapshot 8.4. b. Product offerings 8.4. c. Growth strategies 8.4. d. Initiatives 8.4. e. Geographical presence 8.4. f. Key numbers 8.5. Pfizer 8.5. a. Company snapshot 8.5. b. Product offerings 8.5. c. Growth strategies 8.5. d. Initiatives 8.5. e. Geographical presence 8.5. f. Key numbers 8.6. Randox Laboratories 8.6. a. Company snapshot 8.6. b. Product offerings 8.6. c. Growth strategies 8.6. d. Initiatives 8.6. e. Geographical presence 8.6. f. Key numbers 8.7. Almac Group 8.7. a. Company snapshot 8.7. b. Product offerings 8.7. c. Growth strategies 8.7. d. Initiatives 8.7. e. Geographical presence 8.7. f. Key numbers 8.8. Novartis AG 8.8. a. Company snapshot 8.8. b. Product offerings 8.8. c. Growth strategies 8.8. d. Initiatives 8.8. e. Geographical presence 8.8. f. Key numbers 8.9. Teva Pharmaceuticals Limited 8.9. a. Company snapshot 8.9. b. Product offerings 8.9. c. Growth strategies 8.9. d. Initiatives 8.9. e. Geographical presence 8.9. f. Key numbers 8.10. CETICS Healthcare Technologies GmbH 8.10. a. Company snapshot 8.10. b. Product offerings 8.10. c. Growth strategies 8.10. d. Initiatives 8.10. e. Geographical presence 8.10. f. Key numbers Chapter 9: Conclusion Chapter 10: Appendix 10.1 List of tables 10.2 Research methodology 10.3 About Netscribes Inc. Note: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research. The report is in progress and will be delivered within 12 business days post payment confirmation

o Abbott Laboratories o GE Healthcare o GlaxoSmithKline (GSK) o Johnson & Johnson o Pfizer o Randox Laboratories o Almac Group o Novartis AG o Teva Pharmaceuticals Limited o CETICS Healthcare Technologies GmbH